Research Paper Volume 13, Issue 9 pp 12431—12455

Identification of a mesenchymal-related signature associated with clinical prognosis in glioma

The effect of glioma cell clone, proliferation, migration and invasion ability after silencing FCGR2A or EHD2. (A, B) Cell proliferation was measured by the MTT assay for 24 hours up to 72 hours. (C, D) Representative imaging (C) or counting (D) of the colonies formed by LN18 cells after silencing with FCGR2A for 7 days. (E–G) Representative imaging (E) or counting (F, G) of migration assays after silencing FCGR2A and EHD2 in glioma cells. (H–J) Representative imaging (H) or counting (I, J) of invasion assays after silencing FCGR2A and EHD2 in glioma cells. *P

Figure 8. The effect of glioma cell clone, proliferation, migration and invasion ability after silencing FCGR2A or EHD2. (A, B) Cell proliferation was measured by the MTT assay for 24 hours up to 72 hours. (C, D) Representative imaging (C) or counting (D) of the colonies formed by LN18 cells after silencing with FCGR2A for 7 days. (EG) Representative imaging (E) or counting (F, G) of migration assays after silencing FCGR2A and EHD2 in glioma cells. (HJ) Representative imaging (H) or counting (I, J) of invasion assays after silencing FCGR2A and EHD2 in glioma cells. *P<0.05; **P<0.01; ***P<0.001.